**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 54569

**Manuscript Type:** ORIGINAL ARTICLE

**Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer**

Timudom K *et al*. Cancer related-inflammatory markers and rectal cancer

Kitinat Timudom, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Ananya Pongpaibul, Pornpim Korpraphong, Janjira Petsuksiri, Suthinee Ithimakin, Atthaphorn Trakarnsanga

**Kitinat Timudom, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Atthaphorn Trakarnsanga,** Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

**Ananya Pongpaibul,** Department of Pathology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

**Pornpim Korpraphong, Janjira Petsuksiri,** Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

**Suthinee Ithimakin,** Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

**Author contributions:** Trakarnsanga A was involved in the conceptualization, project administration, writing review and editing; Timudom K was involved in data curation, and writing the original draft; Akaraviputh T, Pongpaibul A, Korpraphong P, Petsuksiri J, Ithimakin S and Chinswangwatanakul V were involved in writing review and editing; all authors read and approved the final manuscript.

**Corresponding author:** **Atthaphorn Trakarnsanga, MD, Associated Professor,** Department of Surgery, Faculty of Medicine, Siriraj Hospital, 2 Prannok, Bangkoknoi, Bangkok 10700, Thailand. atthaphorn.tra@mahidol.ac.th

**Received:** February 27, 2020

**Revised:** May 11, 2020

**Accepted:** August 16, 2020

**Published online:**

**Abstract**

BACKGROUND

Locally advanced rectal cancer is treated using neoadjuvant chemoradiation (nCRT), followed by total mesorectal excision (TME). Tumor regression and pathological post-treatment stage are prognostic for oncological outcomes. There is a significant correlation between markers representing cancer-related inflammation, including high neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte (MLR) and unfavorable oncological outcomes. However, the predictive role of these markers on the effect of chemoradiation is unknown.

AIM

To evaluate the predictive roles of NLR, MLR, and PLR in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiation.

METHODS

Patients (*n* = 111) with locally advanced rectal cancer who underwent nCRT followed by TME at the Minimally Invasive Surgery Unit, Siriraj Hospital between 2012 and 2018 were retrospectively analyzed. The associations between post-treatment pathological stages, neoadjuvant rectal (NAR) score and the pretreatment ratios of markers of inflammation (NLR, MLR, and PLR) were analyzed.

RESULTS

Clinical stages determined using computed tomography, magnetic resonance imaging, or both were T4 (*n* = 16), T3 (*n* = 94), and T2 (*n* = 1). The NAR scores were categorized as high (score > 16) in 23.4%, intermediate (score 8-16) in 41.4%, and low (score < 8) in 35.2%. The mean values of the NLR, PLR, and MLR correlated with pathological tumor staging (ypT) and the NAR score. The values of NLR, PLR and MLR were higher in patients with advanced pathological stage and high NAR scores, but not statistically significant.

CONCLUSION

In patients with locally advanced rectal cancer, pretreatment NLR, MLR and PLR are higher in those with advanced pathological stage but the differences are not significantly different.

**Key words:** Locally advanced rectal cancer; Cancer-related inflammatory markers; Neoadjuvant chemoradiation; Neutrophil-to-lymphocyte ratio; Monocyte-to-lymphocyte ratio; Platelet-to-lymphocyte ratio

Timudom K, Akaraviputh T, Chinswangwatanakul V, Pongpaibul A, Korpraphong P, Petsuksiri J, Ithimakin S, Trakarnsanga A. Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer. *World J Gastrointest Surg* 2020; In press

**Core tip:** Previously, correlations between markers representing cancer-related inflammation, including high neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) and unfavorable oncological outcomes have been reported. The present study demonstrated the predictive role of these markers in patients with locally advanced rectal cancer. Pretreatment NLR, MLR, and PLR were higher in those with advanced pathological stage and high neoadjuvant rectal score, and represented a poor outcome.

**INTRODUCTION**

In Thailand, colorectal cancer is the third most common cancer, and approximately one-third of Thai patients with colorectal cancer have metastatic disease[1]. Neoadjuvant chemoradiation (nCRT) followed by total mesorectal excision (TME) is the preferred treatment for locally advanced rectal cancer (clinical stage T3 or T4 or node-positive disease). This treatment regimen provides many benefits, including improved local control and reduced toxicity. Although a complete pathological response to this therapeutic regimen (ypT0N0) is a strong prognostic factor, we still lack precise preoperative prognostic and predictive factors for locally advanced rectal cancer. Therefore, surgical removal of the rectum remains the standard treatment and is essential in all patients.

Here we investigated the value of preoperative biochemical markers as prognostic factors and predictive markers for nCRT. Inflammation status correlates with the oncological outcomes of patients with rectal cancer[2-5]. The immune system acts on cancer cells by producing numerous cytokines and mediators of inflammation. The neutrophil-to-lymphocyte ratio (NLR) serves as the primary prognostic marker of white blood cell status. Previous meta-analyses demonstrated the benefit of the NLR as a prognostic factor for worse oncological outcomes in various cancers including endometrial cancer, non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, and colorectal cancer[6,7]. Subsequently, the predictive roles of the monocyte-to-lymphocyte ratio (MLR) and the platelet-to-lymphocyte ratio (PLR) were established[8]. Both pre- and post-chemoradiation NLR were prognostic of worse disease-free and overall survival among locally advanced cancer patients[9,10]. However, the predictive role of these markers in patients receiving nCRT is still inconclusive. Here, we evaluate the predictive roles of pretreatment NLR, MLR, and PLR in patients with locally advanced rectal cancer receiving nCRT.

**MATERIALS AND METHODS**

The records of 111 patients with locally advanced rectal cancer who underwent nCRT followed by oncological surgical resection at the Minimally Invasive Surgery Unit, Siriraj Hospital between June 2012 and January 2018 were retrospectively analyzed. Thirty-six patients (32.4%) were diagnosed with mid-rectal cancer, defined as a tumor located 5–10 cm from the anal verge, and 75 patients (67.6%) were diagnosed with low-rectal cancer, defined as a tumor located within 5 cm from the anal verge. Clinical staging was performed using magnetic resonance imaging (MRI), computed tomography (CT) or both, with or without endorectal ultrasound (ERUS). Patients with evidence of distant metastasis on preoperative staging were excluded from the study. Demographic data collected included age, sex, clinical tumor and nodal stages, and location of tumors. A complete blood count examination was performed at baseline before starting nCRT in all patients. All patients received standard long-term nCRT comprising 45.0 to 50.4 Gy in twenty-eight fractions, infusion of 5-fluorouracil for five days during the first and fifth weeks of radiation, or continuous oral capecitabine therapy.

All patients underwent oncological resection after completing nCRT at intervals ranging from six to thirteen weeks depending on the clinical response, scheduling, and the surgeon’s preference. High ligation of inferior mesenteric vessels and total mesorectal excision were performed. Pathologists specializing in gastroenterology examined the surgical specimens. Pathological tumor (ypT0-4) and nodal staging (ypN0-2) data were acquired. A pathological complete response was defined as no detectable viable tumor cells in the resected specimen (ypT0) and the resected node (ypN0). The neoadjuvant rectal (NAR) score was calculated according to the data generated using a Valentini nomogram for overall survival, using the clinical tumor stage (cT), pathological tumor stage (pT), and pathological nodal stage (pN)[6,11]. The equation for calculating the NAR score is as follows: NAR = [5ypN – 3(cT – ypT) + 12]2/9.61. NAR scores were categorized into the following levels: high (score > 16), intermediate (score 8-16) and low (score < 8)[11,12]. High NAR scores correlated with poor oncological outcomes. Posttreatment pathological stages and ratios of markers of inflammation (pretreatment NLR, MLR, and PLR ratios) were compared.

***Statistical analysis***

Statistical analysis of all collected data was performed with SPSS version 19.0 (IBM Corporation, Armonk, NY, United States). All demographic data were analyzed using descriptive statistics. Numerical variables are expressed using frequency. Continuous variables were compared using independent samples Kruskal-Wallis (one-way ANOVA) test. A *P* value of < 0.05 was considered statistically significant.

**RESULTS**

Patient demographic data are shown in Table 1. Sixty-six patients were male and 45 were female with a median age of 61 years (range, 22–93 years). The clinical stages determined using CT, MRI, or both were as follows: T4 (*n* = 16), T3 (*n* = 94), and T2 (*n* = 1). Clinically positive lymph nodes were found in 16 patients (14.4%). The NAR scores were categorized as high (> 8), intermediate (8–16), and low (< 8) in 23.4%, 41.4% and 35.2%, respectively.

The mean values of the pretreatment NLR, PLR, and MLR correlated with pathologic tumor staging (ypT) and the NAR score. The mean values of the NLR of pathological stages 0, 1, 2, and 3 were 2.36, 2.42, 2.83 and 3.07, respectively (*P* = 0.40) (Figure 1). The mean values of the MLR of pathological stages 0, 1, 2 and 3 were 0.24, 0.27, 0.28, and 0.36, respectively (*P* = 0.18). The mean values of the PLR of pathological stages 0, 1, 2, and 3 were 10.15, 13.27, 14.20 and 15.56, respectively (*P* = 0.54). The mean values of the NLR were 2.52, 2.61, and 3.08 for low, intermediate, and high NAR scores, respectively (*P* = 0.58). The mean values of the MLR were 0.25, 0.27, and 0.37, respectively (*P* = 0.32). The mean values of the PLR were 11.40, 13.20, and 16.00, respectively (*P* = 0.61).

Twenty patients (76.9%) with low NARs experienced pathological complete responses. Furthermore, 34 patients (73.9%) with intermediate NAR scores and 37 patients (94.9%) with high NAR scores had pathological stages 2 and 3.

**DISCUSSION**

Our study demonstrated that the mean values of the NLR, PLR, and MLR correlated with pathological tumor staging and the NAR score. The ratios were higher in advanced pathological stages and high NAR scores. However, the differences were not statistically significant among the groups due to the small number of patients which is the main limitation of this study.

The systemic inflammatory response to cancer is increased in various cancers including lung cancer, ovarian cancer, tissue sarcoma, and colorectal cancer[6]. The pathophysiology by which the inflammatory pathway might affect cancer is unknown. There is evidence to indicate an association between inflammation and impaired nutritional status. Inflammatory bowel disease serves as a good example, as colorectal cancer can develop in patients with chronic inflammatory bowel disease[13].

The level of the systemic inflammatory response is determined by the concentration of C-reactive protein, which serves as a marker of acute phase protein stimulated by interleukin (IL)-6[14-16]. The Glasgow prognostic score serves as a prognostic factor[17]. However, these laboratory markers are not routinely measured during the preoperative evaluation of the majority of patients with rectal cancer, but complete blood counts are routinely examined.

T-cell lymphocytes play a major role in the antitumor immune response. The systemic inflammatory response is associated with lymphocytopenia and diminished lymphocyte function caused by the release of numerous proinflammatory cytokines such as IL-10 and transforming growth factor beta. Lymphocytopenia is the major contributor to high NLR, MLR, and PLR values. The low number of lymphocytes in the peripheral circulation may indicate a low antitumor response. CD8+ T lymphocytes play a major role in cancer immunity by killing cancer cells[18]. Tumor–associated macrophages are associated with angiogenesis and tumor invasion[19]. Thrombocytosis reflects cancer-induced inflammation. Furthermore, high concentrations of IL-1 and IL-6 were found in patients’ plasma or cultured supernatants of tumor cells obtained from patients with thrombocytosis and tumors that produce colony-stimulating factor[20]. A meta-analysis of 959 patients suggested that a high NLR is significantly associated with shorter overall survival, disease-free survival, and recurrence-free survival[7].

The NAR score predicts the prognosis of patients with rectal cancer who receive nCRT. According to the NSABP R-04 trial, NAR scores were categorized as low, intermediate, and high, which were significantly associated with overall survival[6]. In the present study, the mean values of pretreatment NLR, MLR, and PLR gradually increased as a function of the NAR score. These scores reflect an association between the levels of these markers and survival, although we did not demonstrate a significant association in the present study. However, in patients with high pretreatment NLR, MLR, and PLR, standard nCRT is warranted. We observed a restricted response to nCRT among patients with with a high NAR score and high ratios of these inflammatory markers. Alternatively, upfront chemotherapy or a total neoadjuvant approach may play an important role in these patients.

The limitations of this study include its retrospective analysis of a small number of patients at a single center.

In summary, pretreatment NLR, MLR, and PLR in patients with locally advanced rectal cancer treated with nCRT were higher in patients with advanced pathological stages, although the differences were not statistically significant. Further studies with larger populations are required to evaluate the role of these inflammatory markers in predicting patient outcomes.

**ARTICLE HIGHLIGHTS**

***Research background***

The systemic inflammatory response is increased in cancer. The level of the systemic inflammatory response is indicated by the concentration of C-reactive protein or the Glasgow prognostic score. However, these laboratory markers are not routinely measured. The neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR) and the platelet-to-lymphocyte ratio (PLR) from the complete blood count are prognostic for various cancers.

***Research motivation***

The NLR, MLR and PLR are associated with poor oncological outcomes in rectal cancer. However, the predictive role of these markers in patients receiving preoperative chemoradiation is inconclusive.

***Research objectives***

We evaluated the predictive roles of pretreatment NLR, MLR, and PLR in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiation.

***Research methods***

The records of patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiation followed by surgical resection at Siriraj Hospital between 2012 and 2018 were retrospectively analyzed. The associations between posttreatment pathological stages, neoadjuvant rectal (NAR) score and the pretreatment ratios of markers of inflammation (NLR, MLR, and PLR) were analyzed.

***Research results***

Among 111 patients, the clinical stages determined using computed tomography, magnetic resonance imaging, or both were as follows: T4 (*n* = 16), T3 (*n* = 94), and T2 (*n* = 1). The frequency of clinically positive lymph nodes was 14.4%. The NAR scores were categorized as high (> 8) in 23.4%, intermediate (8–16) in 41.4%, and low (< 8) in 35.2%. The mean values of the NLR of pathological stages 0, 1, 2, and 3 were 2.36, 2.42, 2.83 and 3.07, respectively (*P* = 0.40) (Figure 1). The mean values of the MLR of pathological stages 0, 1, 2 and 3 were 0.24, 0.27, 0.28, and 0.36, respectively (*P* = 0.18). The mean values of the PLR of pathological stages 0, 1, 2, and 3 were 10.15, 13.27, 14.20 and 15.56, respectively (*P* = 0.54). The mean values of the NLR were 2.52, 2.61, and 3.08 for low, intermediate, and high NAR scores, respectively (*P* = 0.58). The mean values of the MLR were 0.25, 0.27, and 0.37, respectively (*P* = 0.32). The mean values of the PLR were 11.40, 13.20, and 16.00, respectively (*P* = 0.61).

***Research conclusions***

The pretreatment NLR, MLR, and PLR of patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by total mesorectal excision were higher in patients with advanced pathological stages, although the differences were not statistically significant.

***Research perspectives***

This study demonstrated the association between higher numbers of pretreatment inflammatory markers and higher advanced stages. Furthermore, higher numbers of pretreatment NLR, MLR, and PLR were associated with poorer response to neadjuvant chemoradiation (high NAR score). Unfortunately, this is a retrospective analysis of a small number of patients at a single center. Therefore, there were no statistically significant results. Further studies of larger populations are required to evaluate the significance of these inflammatory markers in predicting the response.

**ACKOWLEDGEMENTS**

We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

**REFERENCES**

1 **Techawathanawanna S**, Nimmannit A, Akewanlop C. Clinical characteristics and disease outcome of UICC stages I-III colorectal cancer patients at Siriraj Hospital. *J Med Assoc Thai* 2012; **95 Suppl 2**: S189-S198 [PMID: 22574549]

2 **Dudani S**, Marginean H, Tang PA, Monzon JG, Raissouni S, Asmis TR, Goodwin RA, Gotfrit J, Cheung WY, Vickers MM. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. *BMC Cancer* 2019; **19**: 664 [PMID: 31277604 DOI: 10.1186/s12885-019-5892-x]

3 **Braun LH**, Baumann D, Zwirner K, Eipper E, Hauth F, Peter A, Zips D, Gani C. Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable? *Int J Mol Sci* 2019; **20**: 2448 [PMID: 31108935 DOI: 10.3390/ijms20102448]

4 **Nagasaki T**, Akiyoshi T, Fujimoto Y, Konishi T, Nagayama S, Fukunaga Y, Ueno M. Prognostic Impact of Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Low Rectal Cancer Treated with Preoperative Chemoradiotherapy. *Dig Surg* 2015; **32**: 496-503 [PMID: 26544755 DOI: 10.1159/000441396]

5 **Shen L**, Zhang H, Liang L, Li G, Fan M, Wu Y, Zhu J, Zhang Z. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. *Radiat Oncol* 2014; **9**: 295 [PMID: 25518933 DOI: 10.1186/s13014-014-0295-2]

6 **Templeton AJ**, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014; **106**: dju124 [PMID: 24875653 DOI: 10.1093/jnci/dju124]

7 **Dong YW**, Shi YQ, He LW, Su PZ. Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: a meta-analysis. *Onco Targets Ther* 2016; **9**: 3127-3134 [PMID: 27307753 DOI: 10.2147/OTT.S103031]

8 **Lee IH**, Hwang S, Lee SJ, Kang BW, Baek D, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Cho SH, Kim JG. Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. *Anticancer Res* 2017; **37**: 1459-1465 [PMID: 28314318 DOI: 10.21873/anticanres.11470]

9 **Sung S**, Son SH, Park EY, Kay CS. Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy. *PLoS One* 2017; **12**: e0173955 [PMID: 28291841 DOI: 10.1371/journal.pone.0173955]

10 **Cha YJ**, Park EJ, Baik SH, Lee KY, Kang J. Prognostic impact of persistent lower neutrophil-to-lymphocyte ratio during preoperative chemoradiotherapy in locally advanced rectal cancer patients: A propensity score matching analysis. *PLoS One* 2019; **14**: e0214415 [PMID: 30901357 DOI: 10.1371/journal.pone.0214415]

11 **George TJ Jr**, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. *Curr Colorectal Cancer Rep* 2015; **11**: 275-280 [PMID: 26321890 DOI: 10.1007/s11888-015-0285-2]

12 **Fokas E**, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C, Sauer R, Kaufmann M, Hothorn T, Rödel C; German Rectal Cancer Study Group. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. *Ann Oncol* 2018; **29**: 1521-1527 [PMID: 29718095 DOI: 10.1093/annonc/mdy143]

13 **Kim ER**, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. *World J Gastroenterol* 2014; **20**: 9872-9881 [PMID: 25110418 DOI: 10.3748/wjg.v20.i29.9872]

14 **Pathak S**, Nunes QM, Daniels IR, Smart NJ. Is C-reactive protein useful in prognostication for colorectal cancer? A systematic review. *Colorectal Dis* 2014; **16**: 769-776 [PMID: 25039573 DOI: 10.1111/codi.12700]

15 **Kersten C**, Louhimo J, Ålgars A, Lahdesmaki A, Cvancerova M, Stenstedt K, Haglund C, Gunnarsson U. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. *Acta Oncol* 2013; **52**: 1691-1698 [PMID: 24102179 DOI: 10.3109/0284186X.2013.835494]

16 **Guthrie GJ**, Roxburgh CS, Richards CH, Horgan PG, McMillan DC. Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. *Br J Cancer* 2013; **109**: 131-137 [PMID: 23756867 DOI: 10.1038/bjc.2013.291]

17 **McMillan DC**. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. *Cancer Treat Rev* 2013; **39**: 534-540 [PMID: 22995477 DOI: 10.1016/j.ctrv.2012.08.003]

18 **Hoffmann TK**, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. *Clin Cancer Res* 2002; **8**: 2553-2562 [PMID: 12171883]

19 **Pollard JW**. Trophic macrophages in development and disease. *Nat Rev Immunol* 2009; **9**: 259-270 [PMID: 19282852 DOI: 10.1038/nri2528]

20 **Suzuki A**, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imura H. Thrombocytosis in patients with tumors producing colony-stimulating factor. *Blood* 1992; **80**: 2052-2059 [PMID: 1382717]

**Footnotes**

**Institutional review board statement:** This study was approved by Siriraj’s institutional review board committee and the committee’s reference number is 335/2561(EC4).

**Informed consent statement:** All patient information is de-identified.

**Conflict-of-interest statement:** The authors declare that they have no competing interests

**Data sharing statement:** The dataset utilized during the current study is available within the institutional collected data system which was used under Siriraj’s institutional review board committee approval for this study. Data are available upon reasonable request with permission of Siriraj’s institutional review board committee.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 27, 2020

**First decision:** April 22, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Thailand

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C


Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Burke DA **S-Editor:** Zhang H **L-Editor:** Webster JR **E-Editor:**

**Figure Legends**

****

****

**Figure 1 Mean values of** **the neutrophil-to-lymphocyte ratio, the** **monocyte-to-lymphocyte ratio and the** **platelet-to-lymphocyte ratio by stage.** NLR: Neutrophil-to-lymphocyte ratio; MLR: Monocyte-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio.

**Table 1 Demographic data**

|  |  |  |
| --- | --- | --- |
|  | ***n* (111)** | **%** |
| Median age (yr) | 61 |  |
| Sex |  |  |
| Male | 66 | 59.5 |
| Female | 45 | 40.5 |
| Tumor location |  |  |
| Middle rectum | 36 | 32.4 |
| Lower rectum | 75 | 67.6 |
| Clinical T staging |  |  |
| cT2 | 1 | 1 |
| cT3 | 94 | 84 |
| cT4 | 16 | 15 |
| Lymph node status |  |  |
| Positive (cN+) | 16 | 14.4 |
| Negative (cN-) | 95 | 85.6 |
| NAR score |  |  |
| Low | 26 | 23.4 |
| Intermediate | 46 | 41.4 |
| High | 39 | 35.2 |

NAR: Neoadjuvant rectal.